| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CDK2-IN-73 targets cyclin-dependent kinase 2 (CDK2), a key regulator of the cell cycle that controls the G1/S transition and DNA replication. By inhibiting CDK2/cyclin A, the compound disrupts cell cycle progression, leading to antiproliferative effects. It has an IC50 of 44 nM for CDK2/cyclin A and is 2,000-fold more selective for CDK2 than CDK1/cyclin B.
|
|---|---|
| ln Vitro |
CDK2-IN-73 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A. It is 2,000-fold more selective for CDK2 over CDK1/cyclin B (IC50 = 86 μM). It is selective for CDK2 over CDK1, CDK4, CDK7, and CDK9 at 100 μM. The compound's high selectivity makes it a valuable tool for studying CDK2-specific functions.
|
| ln Vivo |
Specific in vivo activity data for CDK2-IN-73 is not extensively detailed in the available literature. As a potent and selective CDK2 inhibitor, it has potential therapeutic applications in various types of cancer. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
CDK2-IN-73's activity as a CDK2 inhibitor is assessed using in vitro kinase assays. These assays measure the compound's ability to inhibit the phosphorylation activity of CDK2/cyclin A. The IC50 of 44 nM is determined from dose-response curves. Selectivity profiling against other kinases, including CDK1, CDK4, CDK7, and CDK9, is performed to evaluate its specificity.
|
| Cell Assay |
Cellular assays for CDK2-IN-73 involve treating cancer cell lines with the compound and measuring cell proliferation and viability. The compound's ability to induce cell cycle arrest is assessed using flow cytometry. Its effects on CDK2 activity in cells can be evaluated by measuring the phosphorylation of its substrates.
|
| Animal Protocol |
In vivo animal model protocols for CDK2-IN-73 would involve its administration to tumor-bearing mice to evaluate its antitumor efficacy. The compound's effects on tumor growth, cell cycle progression, and survival would be assessed. Pharmacokinetic studies would evaluate its absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
CDK2-IN-73 has a molecular weight of 442.49 and a molecular formula of C23H18N6O2S. Specific pharmacokinetic data is not extensively detailed in the available literature. As a small molecule inhibitor, its pharmacokinetic properties would need to be evaluated in preclinical studies.
|
| Toxicity/Toxicokinetics |
The toxicological profile of CDK2-IN-73 has not been extensively characterized. As a research compound, it is intended for research use only and not for human consumption. Standard safety assessments would be required for clinical development.
|
| References | |
| Additional Infomation |
CDK2-IN-73 (CAS# 2079895-42-2) is a research compound used to study the role of CDK2 in cell cycle regulation and cancer. It is a potent and highly selective CDK2 inhibitor with an IC50 of 44 nM and 2,000-fold selectivity over CDK1. It is not approved for clinical use and is supplied as a research chemical.
|
| Molecular Formula |
C23H18N6O2S
|
|---|---|
| Molecular Weight |
442.493022441864
|
| Exact Mass |
442.121
|
| CAS # |
2079895-42-2
|
| PubChem CID |
123132899
|
| Appearance |
Light brown to brown solid powder
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC(=CC=1)NC1N=C2C(=C(C3C=CC=C(C4C=CC=CC=4)C=3)N=1)NC=N2)(N)(=O)=O
|
| InChi Key |
FUGRWXRQJGJIER-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H18N6O2S/c24-32(30,31)19-11-9-18(10-12-19)27-23-28-20(21-22(29-23)26-14-25-21)17-8-4-7-16(13-17)15-5-2-1-3-6-15/h1-14H,(H2,24,30,31)(H2,25,26,27,28,29)
|
| Chemical Name |
4-[[6-(3-phenylphenyl)-7H-purin-2-yl]amino]benzenesulfonamide
|
| Synonyms |
CDK2IN73; CDK2 IN 73; CDK2-IN-73
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.83 mg/mL (~47.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2599 mL | 11.2997 mL | 22.5994 mL | |
| 5 mM | 0.4520 mL | 2.2599 mL | 4.5199 mL | |
| 10 mM | 0.2260 mL | 1.1300 mL | 2.2599 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
